AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL trial and promised to share more at an upcoming scientific meeting.

In its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $1.09 per share, reflecting an increase of 10.1% compared to the same period last year.

Dozens of alumni of a group the State Department has linked to espionage have secured jobs in sensitive industries.

The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused ...

AstraZeneca (NASDAQ:AZN) announced Thursday that gefurulimab, its experimental injectable for generalized myasthenia gravis, ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

The Washington, D.C.–Baltimore area ranks in the top six for life sciences R&D and manufacturing talent, according to a CBRE report. The Maryland Department of Commerce’s director of life sciences ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised ...

RICHMOND, Va. (WDBJ) - AstraZeneca is deciding where in Virginia it will establish its newest multi-billion dollar ...

UK-based pharmaceutical giant AstraZeneca plans to build its largest drug manufacturing facility in Virginia, creating ...